Post‐prandial glucose (mmol/L)

Study	Description	Liraglutide 1.8 mg daily	Placebo	Comments
L ‐ LEAD 1 Marre 2009	average of values obtained 90 min after breakfast, lunch and evening meal	‐2.7 mmol/L	‐0.4 mmol/L	Liraglutide 1.8 mg versus placebo: P < 0.0001
L ‐ LEAD 2 Nauck 2009	from self‐monitored 7‐point plasma glucose measurements	‐2.6 mmol/L	‐0.6 mmol/L	Liraglutide 1.8 mg versus placebo: P < 0.001
L ‐ LEAD 4 Zinman 2009	from self‐monitored 7‐point plasma glucose measurements	‐2.7 mmol/L	‐0.8 mmol/L	Liraglutide 1.8 mg versus placebo: P < 0.001; the postprandial increment (postmeal value minus premeal) was significantly reduced over breakfast with liraglutide treatment (‐0.9, ‐0.8, ‐0.3 mmol/L respectively; P < 0.05 for both liraglutide groups versus placebo) but not for lunch and dinner.
L ‐ LEAD 5 Russell‐J 2009	from self‐monitored 7‐point plasma glucose measurements	‐1.81 mmol/L	‐0.03 mmol/L	Liraglutide 1.8 mg versus placebo: P < 0.0001; there was a statistically significantly higher likelihood of achieving ADA targets for PPG (≤ 10 mmol/l) (P < 0.0001) with liraglutide versus placebo.